市场趋势
短期 | 中期 | ||
行业 | Biotechnology (US) | 混合的 | 混合的 |
Biotechnology (全球的) | 混合的 | 混合的 | |
股票 | Annexon, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
分析师共识 | 4.0 |
内部交易活动 | NA |
价格波动 | -2.0 |
技术平均移动指标 | -2.5 |
技术振荡指标 | -3.5 |
平均 | -1.00 |
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases. |
|
部门 | Healthcare |
行业 | Biotechnology |
投资方式 | Small Value |
内部持股比例 | 0.50% |
机构持股比例 | 106.10% |
所有权
姓名 | 日期 | 持有股份 |
---|---|---|
Logos Global Management Lp | 30 Sep 2024 | 2,600,000 |
52周波幅 | ||
目标价格波幅 | ||
高 | 30.00 (HC Wainwright & Co., 521.12%) | 购买 |
中 | 23.00 (376.19%) | |
低 | 16.00 (Needham, 231.26%) | 购买 |
平均值 | 23.00 (376.19%) | |
总计 | 2 购买 | |
平均价格@调整类型 | 5.50 |
公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
---|---|---|---|---|
HC Wainwright & Co. | 17 Dec 2024 | 30.00 (521.12%) | 购买 | 4.88 |
15 Nov 2024 | 30.00 (521.12%) | 购买 | 6.12 | |
Needham | 15 Nov 2024 | 16.00 (231.26%) | 购买 | 6.12 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。
投资组合